Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Chimeric CD(Cluster of Differentiation)133 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies

NCT02541370 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT02541370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02541370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Chimeric CD(Cluster of Differentiation)133 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2015
Completion date
June 30, 2019
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid and lymphoid leukemias, brain tumor, breast cancer, colorectal cancer, liver cancer, ovarian tumor, pancreatic cancer